Dopamine D2 receptor occupancy and cognition in schizophrenia

Analysis of the CATIE data

Hitoshi Sakurai, Robert R. Bies, Scott T. Stroup, Richard S E Keefe, Tarek K. Rajji, Takefumi Suzuki, David C. Mamo, Bruce G. Pollock, Koichiro Watanabe, Masaru Mimura, Hiroyuki Uchida

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Introduction: Antipsychotic drugs exert antipsychotic effects by blocking dopamine D2 receptors in the treatment of schizophrenia. However, effects of D2 receptor blockade on neurocognitive function still remain to be elucidated. The objective of this analysis was to evaluate impacts of estimated dopamine D2 receptor occupancy with antipsychotic drugs on several domains of neurocognitive function in patients with schizophrenia in the Clinical Antipsychotic Trials in Intervention Effectiveness (CATIE) trial. Methods: The dataset from the CATIE trial was used in the present analysis. Data were extracted from 410 subjects who were treated with risperidone, olanzapine, or ziprasidone, received assessments for neurocognitive functions (verbal memory, vigilance, processing speed, reasoning, and working memory) and psychopathology, and provided plasma samples for the measurement of plasma antipsychotic concentrations. D2 receptor occupancy levels on the day of neurocognitive assessment were estimated from plasma antipsychotic concentrations, using population pharmacokinetic analysis and our recently developed model. A multivariate general linear model was used to examine effects of clinical and demographic characteristics, including estimated D2 occupancy levels, on neurocognitive functions. Results: D2 occupancy levels showed significant associations with the vigilance and the summary scores. Neurocognitive functions, including vigilance, were especially impaired in subjects who showed D2 receptor occupancy level of >77%. Discussion: These findings suggest a nonlinear relationship between prescribed antipsychotic doses and overall neurocognitive function and vigilance. This study shows that D2 occupancy above approximately 80% not only increases the risk for extrapyramidal side effects as consistently reported in the literature but also increases the risk for cognitive impairment.

Original languageEnglish
Pages (from-to)564-574
Number of pages11
JournalSchizophrenia Bulletin
Volume39
Issue number3
DOIs
Publication statusPublished - 2013 May

Fingerprint

Dopamine D2 Receptors
Cognition
Antipsychotic Agents
Schizophrenia
Clinical Trials
olanzapine
Risperidone
Psychopathology
Short-Term Memory
Linear Models
Pharmacokinetics
Demography

Keywords

  • antipsychotic
  • cognition
  • dopamine
  • olanzapine
  • risperidone
  • schizophrenia
  • ziprasodine

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Sakurai, H., Bies, R. R., Stroup, S. T., Keefe, R. S. E., Rajji, T. K., Suzuki, T., ... Uchida, H. (2013). Dopamine D2 receptor occupancy and cognition in schizophrenia: Analysis of the CATIE data. Schizophrenia Bulletin, 39(3), 564-574. https://doi.org/10.1093/schbul/sbr189

Dopamine D2 receptor occupancy and cognition in schizophrenia : Analysis of the CATIE data. / Sakurai, Hitoshi; Bies, Robert R.; Stroup, Scott T.; Keefe, Richard S E; Rajji, Tarek K.; Suzuki, Takefumi; Mamo, David C.; Pollock, Bruce G.; Watanabe, Koichiro; Mimura, Masaru; Uchida, Hiroyuki.

In: Schizophrenia Bulletin, Vol. 39, No. 3, 05.2013, p. 564-574.

Research output: Contribution to journalArticle

Sakurai, H, Bies, RR, Stroup, ST, Keefe, RSE, Rajji, TK, Suzuki, T, Mamo, DC, Pollock, BG, Watanabe, K, Mimura, M & Uchida, H 2013, 'Dopamine D2 receptor occupancy and cognition in schizophrenia: Analysis of the CATIE data', Schizophrenia Bulletin, vol. 39, no. 3, pp. 564-574. https://doi.org/10.1093/schbul/sbr189
Sakurai, Hitoshi ; Bies, Robert R. ; Stroup, Scott T. ; Keefe, Richard S E ; Rajji, Tarek K. ; Suzuki, Takefumi ; Mamo, David C. ; Pollock, Bruce G. ; Watanabe, Koichiro ; Mimura, Masaru ; Uchida, Hiroyuki. / Dopamine D2 receptor occupancy and cognition in schizophrenia : Analysis of the CATIE data. In: Schizophrenia Bulletin. 2013 ; Vol. 39, No. 3. pp. 564-574.
@article{3ab867c2696e44ec89a3a549ee8204a8,
title = "Dopamine D2 receptor occupancy and cognition in schizophrenia: Analysis of the CATIE data",
abstract = "Introduction: Antipsychotic drugs exert antipsychotic effects by blocking dopamine D2 receptors in the treatment of schizophrenia. However, effects of D2 receptor blockade on neurocognitive function still remain to be elucidated. The objective of this analysis was to evaluate impacts of estimated dopamine D2 receptor occupancy with antipsychotic drugs on several domains of neurocognitive function in patients with schizophrenia in the Clinical Antipsychotic Trials in Intervention Effectiveness (CATIE) trial. Methods: The dataset from the CATIE trial was used in the present analysis. Data were extracted from 410 subjects who were treated with risperidone, olanzapine, or ziprasidone, received assessments for neurocognitive functions (verbal memory, vigilance, processing speed, reasoning, and working memory) and psychopathology, and provided plasma samples for the measurement of plasma antipsychotic concentrations. D2 receptor occupancy levels on the day of neurocognitive assessment were estimated from plasma antipsychotic concentrations, using population pharmacokinetic analysis and our recently developed model. A multivariate general linear model was used to examine effects of clinical and demographic characteristics, including estimated D2 occupancy levels, on neurocognitive functions. Results: D2 occupancy levels showed significant associations with the vigilance and the summary scores. Neurocognitive functions, including vigilance, were especially impaired in subjects who showed D2 receptor occupancy level of >77{\%}. Discussion: These findings suggest a nonlinear relationship between prescribed antipsychotic doses and overall neurocognitive function and vigilance. This study shows that D2 occupancy above approximately 80{\%} not only increases the risk for extrapyramidal side effects as consistently reported in the literature but also increases the risk for cognitive impairment.",
keywords = "antipsychotic, cognition, dopamine, olanzapine, risperidone, schizophrenia, ziprasodine",
author = "Hitoshi Sakurai and Bies, {Robert R.} and Stroup, {Scott T.} and Keefe, {Richard S E} and Rajji, {Tarek K.} and Takefumi Suzuki and Mamo, {David C.} and Pollock, {Bruce G.} and Koichiro Watanabe and Masaru Mimura and Hiroyuki Uchida",
year = "2013",
month = "5",
doi = "10.1093/schbul/sbr189",
language = "English",
volume = "39",
pages = "564--574",
journal = "Schizophrenia Bulletin",
issn = "0586-7614",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Dopamine D2 receptor occupancy and cognition in schizophrenia

T2 - Analysis of the CATIE data

AU - Sakurai, Hitoshi

AU - Bies, Robert R.

AU - Stroup, Scott T.

AU - Keefe, Richard S E

AU - Rajji, Tarek K.

AU - Suzuki, Takefumi

AU - Mamo, David C.

AU - Pollock, Bruce G.

AU - Watanabe, Koichiro

AU - Mimura, Masaru

AU - Uchida, Hiroyuki

PY - 2013/5

Y1 - 2013/5

N2 - Introduction: Antipsychotic drugs exert antipsychotic effects by blocking dopamine D2 receptors in the treatment of schizophrenia. However, effects of D2 receptor blockade on neurocognitive function still remain to be elucidated. The objective of this analysis was to evaluate impacts of estimated dopamine D2 receptor occupancy with antipsychotic drugs on several domains of neurocognitive function in patients with schizophrenia in the Clinical Antipsychotic Trials in Intervention Effectiveness (CATIE) trial. Methods: The dataset from the CATIE trial was used in the present analysis. Data were extracted from 410 subjects who were treated with risperidone, olanzapine, or ziprasidone, received assessments for neurocognitive functions (verbal memory, vigilance, processing speed, reasoning, and working memory) and psychopathology, and provided plasma samples for the measurement of plasma antipsychotic concentrations. D2 receptor occupancy levels on the day of neurocognitive assessment were estimated from plasma antipsychotic concentrations, using population pharmacokinetic analysis and our recently developed model. A multivariate general linear model was used to examine effects of clinical and demographic characteristics, including estimated D2 occupancy levels, on neurocognitive functions. Results: D2 occupancy levels showed significant associations with the vigilance and the summary scores. Neurocognitive functions, including vigilance, were especially impaired in subjects who showed D2 receptor occupancy level of >77%. Discussion: These findings suggest a nonlinear relationship between prescribed antipsychotic doses and overall neurocognitive function and vigilance. This study shows that D2 occupancy above approximately 80% not only increases the risk for extrapyramidal side effects as consistently reported in the literature but also increases the risk for cognitive impairment.

AB - Introduction: Antipsychotic drugs exert antipsychotic effects by blocking dopamine D2 receptors in the treatment of schizophrenia. However, effects of D2 receptor blockade on neurocognitive function still remain to be elucidated. The objective of this analysis was to evaluate impacts of estimated dopamine D2 receptor occupancy with antipsychotic drugs on several domains of neurocognitive function in patients with schizophrenia in the Clinical Antipsychotic Trials in Intervention Effectiveness (CATIE) trial. Methods: The dataset from the CATIE trial was used in the present analysis. Data were extracted from 410 subjects who were treated with risperidone, olanzapine, or ziprasidone, received assessments for neurocognitive functions (verbal memory, vigilance, processing speed, reasoning, and working memory) and psychopathology, and provided plasma samples for the measurement of plasma antipsychotic concentrations. D2 receptor occupancy levels on the day of neurocognitive assessment were estimated from plasma antipsychotic concentrations, using population pharmacokinetic analysis and our recently developed model. A multivariate general linear model was used to examine effects of clinical and demographic characteristics, including estimated D2 occupancy levels, on neurocognitive functions. Results: D2 occupancy levels showed significant associations with the vigilance and the summary scores. Neurocognitive functions, including vigilance, were especially impaired in subjects who showed D2 receptor occupancy level of >77%. Discussion: These findings suggest a nonlinear relationship between prescribed antipsychotic doses and overall neurocognitive function and vigilance. This study shows that D2 occupancy above approximately 80% not only increases the risk for extrapyramidal side effects as consistently reported in the literature but also increases the risk for cognitive impairment.

KW - antipsychotic

KW - cognition

KW - dopamine

KW - olanzapine

KW - risperidone

KW - schizophrenia

KW - ziprasodine

UR - http://www.scopus.com/inward/record.url?scp=84876592957&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876592957&partnerID=8YFLogxK

U2 - 10.1093/schbul/sbr189

DO - 10.1093/schbul/sbr189

M3 - Article

VL - 39

SP - 564

EP - 574

JO - Schizophrenia Bulletin

JF - Schizophrenia Bulletin

SN - 0586-7614

IS - 3

ER -